Search
Menu
Hemodynamic Monitoring
Hemodynamic Monitoring
Back to products
Hemodynamic Monitoring
Hemodynamic Monitoring
Click to enlarge

Central Blood Pressure Measuring

BP+ provides comprehensive non-invasive cardiovascular assessment from an upper arm cuff and is as easy to use as a conventional BP device.
Central Blood Pressure: Measure aortic systolic and diastolic pressures.
Pulse Wave Analysis: Displays pressure changes at the aorta in a waveform in a 10 second strip that can be analysed by the BP+ Reporter or analysed visually. This can identify arrhythmias and pulse pressure fluctuations (rhythm strip).
Augmentation Index: Highly sensitive measure of vascular tone.
Stand-alone device: Press Start and get results in less than 90 seconds.
Digital patient archive, reporting and trending: BP+ Reporter is the software to accompany the Uscom BP+.
Accurate: Validated against cardiac catheters to surpass SP10, with built-in peripheral calibration.
Repeatable: Strong day-to-day and measure-to-measure repeatability with high intraclass correlation coefficient.
Fast and Comfortable: Complete measurement in less than 90 seconds.
Easy to use: Single upper-arm cuff, with one-button measurement.
Affordable: Advanced cardiovascular monitoring at home care prices.

Contact our experts
Category , , , Brand

Central Blood Pressure
Central blood pressure (BP) is the pressure the heart works against, and it is the strongest predictor of cardiovascular risk.
Central BP is the pressure in the aorta, just near the heart.
Central BP is different from conventional BP measured in the upper arm, which is a 'peripheral' artery. Peripheral BP is usually higher than central BP due to the increased peripheral resistance as the arterial branches increase in number and become smaller. The degree to which the peripheral BP is higher than central BP depends partly on the stiffness of the arteries.

Central BP has been shown to more strongly reflect vascular disease and predict outcomes than traditional upper arm BP. Central BP can also determine the different effects of different hypertension medications when upper arm BP and pulse wave velocity do not. Central BP is the pressure that the heart has to pump against to get blood to flow to the rest of the body. Higher central BP means that the heart consumes more energy to pump blood. This can eventually lead to heart failure. Central BP also reflects the pressure in the blood vessels feeding the brain. If central BP is high, it this may lead to aneurysms and strokes.
Augmentation Index
The augmentation index is a ratio calculated from the pulse pressure waveform, and is a measure of wave reflection and arterial stiffness. Augmentation index is commonly accepted as a measure of the (augmentation) of central aortic pressure by a reflected pulse wave.
Arrhythmias and Heart Rhythm
BP+ provides a 10 second rhythm strip that simplifies identification of abnormal heart rhythms. Atrial fibrillation and premature ventricular contractions can be detected using the rhythm strip.
Arrhythmias and Heart Rhythm irregularities are displayed in more detail on the BP+ Reporter and may be included in printed reports.

Uscom has a mission to demonstrate leadership in science and create non-invasive devices that guide clinicians to improved clinical care and patient outcomes. Uscom is an emerging global leader in non-invasive cardiovascular and pulmonary medical devices, developing innovative technologies to solve the challenges of global disease and health care.
Uscom is driven by a commercial ambition to lead global health innovations and grow shareholder wealth.
The company was founded in 2000 on translational cardiovascular research by Associate Professor Rob Phillips at the University of Queensland. The USCOM 1A was the original device developed and taken to market in 2006, and continues as the cornerstone product of the company. Uscom has sold over 1000 1A units into leading hospitals and clinics worldwide.
Uscom has an aggressive global growth strategy Uscom which has resulted in the acquisition of practice changing and complimentary non-invasive cardiovascular and pulmonary technologies. Uscom acquired Pulsecor Limited in 2013, and Thor Laboratories in 2015.
Uscom are the experts in circulation delivering innovative, practice changing non-invasive cardiovascular and pulmonary monitoring devices. Uscom markets the USCOM 1A advanced hemodynamic monitor, the BP+ and BP+ Reporter, and SpiroSonic digital ultrasonic spirometer series and the proprietary SpiroReporter software. These devices are changing the way cardiovascular and pulmonary medicine is practiced.
Uscom has abundant IP and a strong product pipeline projecting well into the next 10 years. We are looking forward to working with our current key opinion leaders and those that join us to deliver the clinical innovations we are currently working on to patients worldwide. Clinical benefit is the foundation of the value of Uscom and we pride ourselves in creating devices which genuinely contribute to improved care.
For Uscom it is an exciting time as our clinical and commercial value is increasingly being recognised worldwide.
We are proud of the achievements we have delivered to health care over the last 10 years, and we are looking forward to the innovations which we are continuing to develop for delivery over the next 10 years. For Uscom medical innovation is our business, and it is an extremely exciting time and the opportunities are great.

jQuery(document).ready(function($){ $(".wd-entities-title a").each(function(){ var text = $(this).html(); consol.log(text); text = text.replace(/ مدل /g, "
مدل "); $(this).html(text); }); });